Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Targeted Oncology2d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Managed Healthcare Executive2d
Cost-Effectiveness Study: Libtayo “More Favorable” Than Keytruda for First-Line Treatment of Advanced NSCLC
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...
Lung Cancer Research Foundation Announces Research Collaboration with Israel Cancer Research Fund
The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
The American Journal of Managed Care1d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Pharmabiz1d
Innovent receives second fast track designation from US FDA for IBI363 in squamous non-small cell lung cancer
San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
‘It’s working!’ Columbus cancer center is first in Georgia to administer this new therapy
John B. Amos Cancer Center at Piedmont Columbus Regional ’s midtown medical complex is the first in Georgia to offer this ...